Category - Developments

Developments

Seelos posts positive topline data for acute suicidal ideation and behavior in MDD

Seelos Therapeutics (NASDAQ:SEEL) reported positive data from Part 1, the open-label cohort, of its potentially registrational proof-of-concept study of SLS-002, demonstrating a significant treatment effect and a well...

May 17, 2021

Developments

Arctic Vision in exclusive licensing pact with ActualEyes

Arctic Vision of Shanghai and Japanese-based ActualEyes announced an exclusive licensing agreement for Arctic Vision to develop and commercialize ActualEyes’ lead product candidate, AE-101, for the treatment of...

May 14, 2021

Developments

Sio Gene posts CSF reductions with AXO-AAV-GM1 in GM1 ganglioside trial

Sio Gene Therapies (NASDAQ:SIOX) is presenting new biomarker data from the company’s study of AXO-AAV-GM1, its adeno-associated viral vector (AAV)9-based gene therapy candidate for the treatment of GM1 gangliosidosis...

May 13, 2021

Developments

IntelGenx expands psychedelics accord with atai

IntelGenx (TSXV:IGX; OTCQB:IGXT) entered into a second feasibility agreement with atai Life Sciences AG for the development of novel formulations of Salvinorin A, a naturally occurring psychedelic compound being...

May 12, 2021

Developments

Clene presents positive Phase 2 interim ALS efficacy data

Clene (NASDAQ:CLNN) presented positive blinded interim efficacy data from its ongoing Phase 2 RESCUE-ALS clinical trial evaluating the efficacy, safety, pharmacokinetics and pharmacodynamics of CNM-Au8 in the treatment...

May 12, 2021

Developments

IntelGenx shareholders approve atai Life Sciences investment

Shareholders at a virtual annual meeting of IntelGenx Technologies (TSXV:IGX; OTCQB:IGXT) approved atai Life Sciences AG’s investment in IntelGenx. Under the accord, atai initially will acquire an approximate 25%...

May 11, 2021

Developments

Profound Medical, Akumin in U.S. multi-center commercial pact for TULSA-PRO

Profound Medical (NASDAQ:PROF; TSX:PRN) signed a multi-site imaging center agreement for its TULSA-PRO device with Akumin (NASDAQ, TSX:AKU), a leading provider of freestanding, fixed-site outpatient diagnostic imaging...

May 6, 2021

Developments

Hepion Pharma completes patient recruitment in Phase 2a AMBITION trial of CRV431 in advanced NASH

Hepion Pharmaceuticals (NASDAQ:HEPA) completed recruitment for its Phase 2a AMBITION clinical trial, with all non-alcoholic steatohepatitis (NASH) patients in the 225 mg CRV431 dosing cohort now enrolled. After...

May 6, 2021

Developments

Hepion Pharma presents machine learning “learn and confirm” modeling strategy at NASH Congress

Hepion Pharmaceuticals (NASDAQ:HEPA) SVP of clinical pharmacology and analytics, Dr. Patrick Mayo, gave a virtual presentation entitled, “CRV431 – From Benchtop to Bedside Clinical Development” at the 4th Global NASH...

April 29, 2021

Developments

Seelos receives positive EMA orphan drug opinion for SLS-005 in ALS

Seelos Therapeutics (NASDAQ:SEEL) received a positive opinion on European orphan drug designation for SLS-005 in amyotrophic lateral sclerosis (ALS) from the EMA committee for orphan medicinal products. The positive...

April 20, 2021

Category - Developments

Subscribe